This trial studies how well cognitive behavioral therapy or metta-meditation works in reducing distress in caregivers of phase I trial participants. Cognitive behavioral therapy or metta-meditation may help to improve symptoms of psychosocial distress such as depression, anxiety, and stress in caregivers of phase I trial participants.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03557515.
PRIMARY OBJECTIVES:
I. To determine the feasibility of the Phase 1 Caregiver Life Line (P1CaLL) intervention as measured by the recruitment (at least 50% of those approached enroll) and retention (at least 50% of those that initiate sessions complete all sessions) and general acceptability (at least 50% of those that complete the intervention rate it as average or above average on a Likert Scale of acceptability).
SECONDARY OBJECTIVES:
I. To measure changes in distress symptoms as determined by the Depression and Anxiety Stress Scale (DASS) from baseline (week one) to post-assessment (week nine) in caregivers of phase 1 trial participants.
II. Evaluation of between-subject changes in the psychosocial variables from baseline (week one) to post-assessment (week nine) in caregivers of phase 1 trial participants.
EXPLORATORY OBJECTIVES:
I. Exploration of the acceptability of the intervention through a series of qualitative interviews in a subsample of participants.
OUTLINE:
Participants undergo cognitive behavioral therapy (CBT) consisting of a telephonic session covering stress management over 45-60 minutes once weekly for 4 weeks.
Participants are then randomized to 1 of 2 arms.
ARM A: Participants undergo CBT consisting of a telephonic session over 45-60 minutes once weekly for 4 weeks.
ARM B: Participants undergo metta-meditation consisting of a telephonic session and audio recordings over 45-60 minutes once weekly for 4 weeks.
After completion of study, participants are followed up at week 9.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationUCHealth University of Colorado Hospital
Principal InvestigatorKristin Kilbourn